News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

INCOGEN Receives Additional Funding For Cancer Diagnostics Research

10/19/2005 5:10:57 PM

WILLIAMSBURG, Va.--(BUSINESS WIRE)--April 19, 2004--INCOGEN has announced that it received a two-year, $2 Million award from the National Institutes of Health - National Cancer Institute to continue its research program in cancer diagnostics. The research program involves a close collaboration with scientists from the College of William and Mary and clinical researchers from the Eastern Virginia Medical School.

The award is a Phase II follow-on to a previous grant which INCOGEN received from the NIH a year ago. The Phase I award provided funding for INCOGEN and its academic collaborators to develop a pilot project in the analysis of data obtained from surface-enhanced laser desorption ionization (SELDI) mass spectrometry. This approach may provide alternative, highly accurate methods for screening for cancers that currently require invasive diagnoses, such as prostate cancer or leukemia. SELDI was developed by the Fremont, CA-based company Ciphergen, who makes and distributes the instruments used for this research.

"We are delighted to continue working on this important project. The Phase II funding will allow us to continue to take advantage of the world-class expertise in data analysis and experimental research at William and Mary, and also the state-of-the-art proteomics and SELDI work at Eastern Virginia Medical School," said Dr. Maciek Sasinowski, INCOGEN Founder and CEO. "INCOGEN came to Virginia two-and-a-half years ago to foster collaborations among academic institutions in the Commonwealth and to act as the 'glue' between computational science and life science experts. Our current work with W&M and EVMS is a terrific success story of just how fruitful this type of collaboration can be."

Under the award, both institutions will act as subcontractors to INCOGEN. The data will be produced at EVMS and analyzed at both INCOGEN and W&M. The goal of the Phase II research is to develop a ready-to-use, clinical diagnostic software package, based on INCOGEN's highly successful Visual Integrated Bioinformatics Environment (VIBE) software. The new software product will be distributed to clinical researchers involved in diagnostic work.


INCOGEN, Inc. provides state-of-the-art software and industry-leading professional services to scientists involved in pharmaceutical, agricultural and biotechnology research. The suite of INCOGEN tools includes GenePort(R), a web-browser-based information mining and management portal; VIBE(TM), an extensible bioinformatics visual programming and workflow management platform; and HDFR(TM) and Magelan(TM), two image analysis software packages. INCOGEN Professional Services provide scientists with industry-leading technological expertise to assist researchers with every phase of design, development and implementation of their informatics infrastructures. The company is committed to supplying the research community with tools to optimize the analysis, mining, and management of life science data.


INCOGEN, Inc. Don Van Dyke, 919-510-8907; Fax, 919-781-7687;;

Read at

comments powered by Disqus